Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average – Here’s What Happened

Seres Therapeutics, Inc. (NASDAQ:MCRB)’s stock price passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $15.84 and traded as low as $14.84. Seres Therapeutics shares last traded at $15.15, with a volume of 52,611 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Seres Therapeutics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Seres Therapeutics presently has an average rating of “Reduce” and an average target price of $14.33.

Seres Therapeutics Stock Performance

The company has a 50-day moving average of $15.84 and a 200-day moving average of $16.85. The stock has a market capitalization of $137.11 million, a price-to-earnings ratio of -4.24 and a beta of 0.22.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MCRB. Bank of America Corp DE grew its holdings in shares of Seres Therapeutics by 2,772.6% during the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock worth $103,000 after buying an additional 5,157 shares in the last quarter. Vontobel Holding Ltd. boosted its position in Seres Therapeutics by 22.6% during the third quarter. Vontobel Holding Ltd. now owns 98,511 shares of the biotechnology company’s stock worth $1,895,000 after acquiring an additional 18,186 shares during the last quarter. Vanguard Group Inc. grew its stake in Seres Therapeutics by 6.8% in the 3rd quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company’s stock worth $6,001,000 after acquiring an additional 19,793 shares during the period. Goldman Sachs Group Inc. raised its holdings in Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 21,679 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Seres Therapeutics during the 2nd quarter worth $249,000. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical?stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.